 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | CAR-NK-CD19 cells / Beijing Boren Hospital
New P1 trial: Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov) - Jun 7, 2022
P1, N=15, Recruiting, Sponsor: Beijing Boren Hospital